StockData
Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc. (XENE) stock

XENENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$38.78−0.48 (-1.22%)

Close on Nov 17, 2026Market cap $3.76BP/E –Yield –

Xenon Pharmaceuticals cash

Cash and short-term investments held at the end of each period.

Xenon Pharmaceuticals's cash was $930.69M at Jun 30, 2026. For fiscal 2025 it was $548.89M, down 12.4% from the year before. Over ten years it grew 25.1% a year on average. The highest annual figure on record is $638.08M in fiscal 2023.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$548.89M-12.4%
FY2024Dec 31, 2024$626.91M-1.8%
FY2023Dec 31, 2023$638.08M+7.8%
FY2022Dec 31, 2022$592.09M+7.3%
FY2021Dec 31, 2021$551.77M+211.7%
FY2020Dec 31, 2020$177.00M+25.2%
FY2019Dec 31, 2019$141.36M+18.5%
FY2018Dec 31, 2018$119.31M+173.2%
FY2017Dec 31, 2017$43.67M-31.9%
FY2016Dec 31, 2016$64.15M+9.4%
FY2015Dec 31, 2015$58.65M-30.2%
FY2014Dec 31, 2014$84.04M+70.6%
FY2013Dec 31, 2013$49.28M-18.1%
FY2012Dec 31, 2012$60.16M+332.0%
FY2011Dec 31, 2011$13.93M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$930.69M+90.9%
Q1 FY2026Mar 31, 2026$1.09B+99.2%
Q4 FY2025Dec 31, 2025$548.89M-12.4%
Q3 FY2025Sep 30, 2025$462.27M-29.3%
Q2 FY2025Jun 30, 2025$487.55M-32.4%
Q1 FY2025Mar 31, 2025$549.63M-21.4%
Q4 FY2024Dec 31, 2024$626.91M-1.8%
Q3 FY2024Sep 30, 2024$654.02M+24.2%
Q2 FY2024Jun 30, 2024$721.54M+33.7%
Q1 FY2024Mar 31, 2024$699.60M+32.7%
Q4 FY2023Dec 31, 2023$638.08M+7.8%
Q3 FY2023Sep 30, 2023$526.67M-17.5%
Q2 FY2023Jun 30, 2023$539.60M-31.5%
Q1 FY2023Mar 31, 2023$527.04M-2.0%
Q4 FY2022Dec 31, 2022$592.09M+7.3%
Q3 FY2022Sep 30, 2022$638.19M+155.7%
Q2 FY2022Jun 30, 2022$788.24M+202.6%
Q1 FY2022Mar 31, 2022$537.94M+95.8%
Q4 FY2021Dec 31, 2021$551.77M+211.7%
Q3 FY2021Sep 30, 2021$249.63M+30.7%
Q2 FY2021Jun 30, 2021$260.52M+28.5%
Q1 FY2021Mar 31, 2021$274.70M+19.6%
Q4 FY2020Dec 31, 2020$177.00M+25.2%
Q3 FY2020Sep 30, 2020$190.93M+101.8%
Q2 FY2020Jun 30, 2020$202.75M+99.2%
Q1 FY2020Mar 31, 2020$229.67M+108.0%
Q4 FY2019Dec 31, 2019$141.36M+18.5%
Q3 FY2019Sep 30, 2019$94.60M-25.6%
Q2 FY2019Jun 30, 2019$101.80M+60.9%
Q1 FY2019Mar 31, 2019$110.43M+214.8%
Q4 FY2018Dec 31, 2018$119.31M+173.2%
Q3 FY2018Sep 30, 2018$127.13M+190.4%
Q2 FY2018Jun 30, 2018$63.27M+22.4%
Q1 FY2018Mar 31, 2018$35.08M-39.5%
Q4 FY2017Dec 31, 2017$43.67M-31.9%
Q3 FY2017Sep 30, 2017$43.77M-37.0%
Q2 FY2017Jun 30, 2017$51.70M–
Q1 FY2017Mar 31, 2017$58.03M–
Q4 FY2016Dec 31, 2016$64.15M–
Q3 FY2016Sep 30, 2016$69.49M–

More Xenon Pharmaceuticals figures

See a number that looks wrong?